Efficacy of Influenza Vaccine in the Elderly

Overall Vaccine Efficacy in Elderly Adults

• The World Health Organization reports that influenza vaccination offers approximately 70% protection in healthy adults, though efficacy is reduced in elderly populations due to immunosenescence 1, 2
• Influenza vaccination in elderly adults (≥65 years) demonstrates substantial efficacy with a 48% reduction in mortality risk and 27% reduction in hospitalization risk 1, 2
• Key efficacy outcomes in community-dwelling adults ≥65 years include a 48% reduction in mortality risk, 27% reduction in hospitalization risk, lower rates of ICU admission, invasive ventilation, and bacterial pneumonia among vaccinated hospitalized patients, and a cost reduction of 2.75% and reduction in years of life lost by over 50% 1, 2, 4

Enhanced Vaccine Formulations: Superior Protection

• High-dose and adjuvanted influenza vaccines consistently outperform standard-dose vaccines in elderly adults and should be preferentially recommended 1, 5, 6
• The Advisory Committee on Immunization Practices (ACIP) recommends preferential use of higher-dose or adjuvanted influenza vaccines for all adults ≥65 years 6

Critical Context: Immunosenescence and Vaccine Response

• Approximately 90% of influenza-related deaths occur in elderly adults, making vaccination essential despite reduced immune responses 5, 8, 7
• Age-related factors affecting vaccine efficacy include immunosenescence, physiological changes, chronic comorbidities, and prior vaccination history 5, 8, 4, 7

Guideline-Based Recommendations

• The Advisory Committee on Immunization Practices (ACIP) recommends that adults ≥65 years receive either Fluzone High-Dose (HD-IIV4) or MF59-adjuvanted quadrivalent influenza vaccine (aQIV) 6
• For adults <65 years, standard-dose influenza vaccines are recommended unless specific immunocompromising conditions exist 6

Practical Implementation

• Do not delay vaccination if only standard-dose vaccine is available, as any influenza vaccine is superior to no vaccination 6
• When both options are available, enhanced formulations should be prioritized for all adults ≥65 years regardless of frailty status, comorbidities, or prior vaccination history 5, 8